Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison, et al.
Hepatology (2017) Vol. 67, Iss. 5, pp. 1754-1767
Open Access | Times Cited: 613

Showing 1-25 of 613 citing articles:

Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3319
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
David Højland Ipsen, Jens Lykkesfeldt, Pernille Tveden‐Nyborg
Cellular and Molecular Life Sciences (2018) Vol. 75, Iss. 18, pp. 3313-3327
Open Access | Times Cited: 1110
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2018) Vol. 65, pp. 37-55
Open Access | Times Cited: 894
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Natascha Roehlen, Émilie Crouchet, Thomas F. Baumert
Cells (2020) Vol. 9, Iss. 4, pp. 875-875
Open Access | Times Cited: 851
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov, Simon Mark Dahl Baunwall, Karen Louise Thomsen, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 16, Iss. 3, pp. 145-159
Closed Access | Times Cited: 742
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 732
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, et al.
Journal of Hepatology (2017) Vol. 68, Iss. 3, pp. 526-549
Open Access | Times Cited: 603
Current and future pharmacological therapies for NAFLD/NASH
Yoshio Sumida, Masashi Yoneda
Journal of Gastroenterology (2017) Vol. 53, Iss. 3, pp. 362-376
Open Access | Times Cited: 601
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome, M. Sasso, Jonathan J Deeks, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 4, pp. 362-373
Open Access | Times Cited: 591
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Robert F. Schwabe, Ira Tabas, Utpal B. Pajvani
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1913-1928
Open Access | Times Cited: 490
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 482
Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities
Yankai Wen, Joeri Lambrecht, Cynthia Ju, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 45-56
Open Access | Times Cited: 479
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Ralf Weiskirchen, Sabine Weiskirchen, Frank Tacke
Molecular Aspects of Medicine (2018) Vol. 65, pp. 2-15
Closed Access | Times Cited: 461
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
Oliver Krenkel, Tobias Puengel, Olivier Govaere, et al.
Hepatology (2017) Vol. 67, Iss. 4, pp. 1270-1283
Closed Access | Times Cited: 449
Metabolic Inflammation and Insulin Resistance in Obesity
Huaizhu Wu, Christie M. Ballantyne
Circulation Research (2020) Vol. 126, Iss. 11, pp. 1549-1564
Open Access | Times Cited: 421
Determinants of fibrosis progression and regression in NASH
Detlef Schuppan, Rambabu Surabattula, Xiaoyu Wang
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 238-250
Closed Access | Times Cited: 419
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 403
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 383
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
I. Pierantonelli, Gianluca Svegliati‐Baroni
Transplantation (2018) Vol. 103, Iss. 1, pp. e1-e13
Open Access | Times Cited: 372
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne
Nature Reviews Endocrinology (2017) Vol. 14, Iss. 2, pp. 99-114
Closed Access | Times Cited: 360
Autoimmune hepatitis
Giorgina Mieli‐Vergani, Diego Vergani, Albert J. Czaja, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 343
Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 335
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
Olivier Govaere, Simon Cockell, Dina Tiniakos, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 572
Open Access | Times Cited: 318
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison, Manal F. Abdelmalek, Stephen H. Caldwell, et al.
Gastroenterology (2018) Vol. 155, Iss. 4, pp. 1140-1153
Closed Access | Times Cited: 308
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
Vlad Ratziu, Arun J. Sanyal, Stephen A. Harrison, et al.
Hepatology (2020) Vol. 72, Iss. 3, pp. 892-905
Open Access | Times Cited: 308
Page 1 - Next Page

Scroll to top